A Randomized, Double‐Blind, Placebo‐Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP‐825) in the Treatment of Acute Migraine (The TARGET Study)
Authors: Cady Roger K. , McAllister Peter J. , Spierings Egilius L.H. , Messina John , Carothers Jennifer , Djupesland Per G. , Mahmoud Ramy A. 
Published: October 2014

Objective

To evaluate the efficacy and safety of AVP‐825, a drug–device combination of low‐dose sumatriptan powder (22 mg loaded dose) delivered intranasally through a targeted Breath Powered device vs an identical device containing lactose powder (placebo device) in the treatment of migraine headache.

Background

Early treatment of migraine headaches is associated with improved outcome, but medication absorption after oral delivery may be delayed in migraineurs because of reduced gastric motility. Sumatriptan powder administered with an innovative, closed‐palate, Bi‐Directional, Breath Powered intranasal delivery mechanism is efficiently absorbed across the nasal mucosa and produces fast absorption into the circulation. Results from a previously conducted placebo‐controlled study of AVP‐825 showed a high degree of headache relief with an early onset of action (eg, 74% AVP‐825 vs 38% placebo device at 1 hour, P < .01).

Methods

In this double‐blind, placebo‐controlled, parallel‐group study in adults with a history of migraine with or without aura, participants were randomized via computer‐generated lists to AVP‐825 or placebo device to treat a single migraine headache of moderate or severe intensity. The primary endpoint was headache relief (defined as reduction of headache pain intensity from severe or moderate migraine headache to mild or none) at 2 hours post‐dose.

Results

Two hundred and thirty patients (116 AVP‐825 and 114 placebo device) were randomized, of whom 223 (112 and 111, respectively) experienced a qualifying migraine headache (their next migraine headache that reached moderate or severe intensity). A significantly greater proportion of AVP‐825 patients reported headache relief at 2 hours post‐dose compared with those using the placebo device (68% vs 45%, P = .002, odds ratio 2.53, 95% confidence interval [1.45, 4.42]). Between‐group differences in headache relief were evident as early as 15 minutes, reached statistical significance at 30 minutes post‐dose (42% vs 27%, P = .03), and were sustained at 24 hours (44% vs 24%, P = .002) and 48 hours (34% vs 20%, P = .01). Thirty‐four percent of patients treated with AVP‐825 were pain‐free at 2 hours compared with 17% using the placebo device (P = .008). More AVP‐825 patients reported meaningful pain relief (patient interpretation) of migraine within 2 hours of treatment vs placebo device (70% vs 45%, P < .001), and fewer required rescue medication (37% vs 52%, P = .02). Total migraine freedom (patients with no headache, nausea, phonophobia, photophobia, or vomiting) reached significance following treatment with AVP‐825 at 1 hour (19% vs 9%; P = .04). There were no serious adverse events (AEs), and no systemic AEs occurred in more than one patient. Chest pain or pressure was not reported, and only one patient taking AVP‐825 reported mild paresthesia. No other triptan sensations were reported.

Conclusions

Targeted delivery of a low‐dose of sumatriptan powder via a novel, closed‐palate, Breath Powered, intranasal device (AVP‐825) provided fast relief of moderate or severe migraine headache in adults that reached statistical significance over placebo by 30 minutes. The treatment was well tolerated with a low incidence of systemic AEs.